Herpes simplex virus (HSV) has often been suggested as progenitor cells or dendritic cells can both be generated at a vector for gene delivery to the nervous system although an effective efficiency of 100% for the second gene. Here it is also capable of infecting many other cell types. HSV transduction with the vector is combined with flow cytomealso has the ability to package large genetic insertions so try allowing GFP-positive cells to be sorted from the the expression of multiple genes from a single virus is untransduced population. Such completely transduced possible. Here we show that a green fluorescent protein populations of quiescent CD34 ϩ hematopoietic progenitor (GFP) expressing HSV1 vector can transduce two primary and dendritic cells cannot easily be achieved by other human cell types -quiescent human CD34 ϩ hematopoietic means, and might thus allow experimental or therapeutic progenitor cells and dendritic cells -which are both hard protocols to be carried out requiring high-level transduction to transduce by other means. We also show that GFP is which would not otherwise be possible. Such an approach an effective marker when expressed from an HSV vector using HSV vectors might also be applicable to other cell in vivo in the mouse brain. When GFP is expressed types for which transduction is as yet unreliable or of low together with a second gene (in this case lacZ) from a sinefficiency. gle virus, transduced GFP-positive CD34 ϩ hematopoietic 3 and here demonstrate gene transfer to hematopoetic progenitor and dendritic cells which are hard to transduce by other means. Herpes viruses also have the advantage that they can accept large insert sizes, which could include multiple genes and/or regulatory elements and which is often not possible with other vector systems such as retro-, adeno-, or adeno-associated viruses where the size of insert is limited (for reviews see Ref. 4) . The ability to express multiple genes might be important in many therapeutic situations such as, for example, in motor neuron disease where it has recently been shown that the use of two neurotrophic factor expressing adenoviruses was more effective at preventing motor neuron degeneration in an animal model than was either virus alone. 5, 6 Similarly multiple gene expression may be useful where a marker for transfected cells is required together with delivery of a 'test' gene in studies of gene function. Alternatively, as we show here, the marker gene can be used for the purification of cells transduced ex vivo to homogeneity when combined with flow cytometry.
Previously, recombinant herpes viruses were often made expressing lacZ as a marker gene (eg see Ref.
2). However, much interest has recently been shown in green fluorescent protein (GFP) as a marker as it allows expression monitoring in live cells, 7 and GFP expressing retro-and adenovirus vectors have been reported. 8, 9 The availability of newer mutants of GFP exhibiting enhanced fluorescence characteristics has considerably improved b a
Figure 1 GFP expression in vitro and in vivo. (a) BHK cells showing a GFP expressing plaque after infection with an HSV vector with a CMV-
GFP insertion into the UL43 gene generated as described previously. the effectiveness of GFP as a marker gene. We have used the EGFP mutant (Clontech) expressed from a recombinant herpes virus vector and shown that GFP can be used as an effective marker gene within the herpes genome both in vitro ( Figure 1a ) and in vivo (Figure 1b ). Here we could detect strong fluorescence in brain slices after intracranial inoculation of a GFP expressing HSV vector into the brains of mice. Moreover, as visualisation of GFP can be carried out under physiological conditions, fluorescence can easily be observed in live cells which raises the possibility of either performing physiological experiments on GFP-positive cells identified as having been transduced in vivo, or of sorting transduced cells from the non-transduced background population using a standard flow cytometer. When combined with the ability of the HSV genome to accept inserts of large size this could allow the delivery of GFP together with a second or multiple proteins with subsequent flow cytometric sorting of the GFP-positive cells. Such a procedure would allow an effective transduction efficiency of 100% for the second protein after sorting, and might thus be useful for many experimental or therapeutic situations. We therefore tested the feasibility of this approach using dendritic and hematopoiteic progenitor cells as target cell types.
Dendritic cells and CD34 + hematopoietic progenitor cells are both cell types which are hard to transfect by many routine methods and which could provide important ex vivo gene transfer targets for either immunotherapy (eg antigen loading of dendritic cells, 10 or cytokine expression in tumor cells 11 ) or corrective gene therapy if effective transduction could be routinely achieved. Although previous experiments using retroviruses and adenoviruses have shown successful transduction of dendritic cells -retroviruses giving approximately 25-65% gene transfer with three rounds of infection over 7 days, 12, 13 and adenoviruses giving up to 95% efficiency 14 -dendritic cell transduction is still problematic. Quiescent CD34
+ hematopoietic progenitor cells cannot be transduced by retroviruses or at only low efficiency with adeno-associated virus (eg see Refs 15 and 16), although adenoviruses have been reported to give up to 45% transduction efficiency, 17 and approximately 90% transduction has recently been reported using an HSV2 mutant originally developed as a vaccine. 18 In both these cases CD34 + cells were derived from bone marrow, whereas the efficiency of transduction using CD34 + cells mobilized into peripheral blood was approximately 25% using an adenovirus vector. 17 However, in our hands, quiescent CD34
+ progenitor cells cannot be transduced with identical adenovirus vectors other than at low efficiency (Ͻ1%, results not shown).
We have now tested an HSV1 vector expressing both GFP (from a CMV promoter) and lacZ (from an RSV promoter) for transduction of dendritic cells and CD34 + hematopoietic progenitor cells, both derived from the peripheral blood of human volunteers/patients. In these experiments we show that HSV1 can be used to transduce these cells at varying efficiency (Ͼ70% for dendritic cells and approximately 10% for hematopoietic progenitor cells; Figure 2 ). Both quiescent (cultured in stem cell factor alone) and cytokine-treated (cultured in stem cell factor, IL3 and IL6) CD34
+ hematopoietic progenitor cells were transduced at equal efficiency in these experiments. Results are thus only shown for quiescent cells. For dendritic cells the transduction efficiency is similar to previous results reported with adenovirus, and shows an improvement for hematopoietic cells which in our hands could not previously be transduced (see above).
Moreover, after cell sorting for GFP-positive cells (Figure 3a) , a 100% lacZ expressing population could routinely be produced for both dendritic and hematopoietic progenitor cells (Figure 3b) . LacZ expression levels appeared somewhat variable in dendritic cells, whereas in hematopoietic progenitor cells expression levels were more uniform. As the virus expresses both GFP and lacZ, and flow cytometric sorting allows the removal of GFPnegative nontransduced cells, resulting cells show an effective transduction efficiency of 100% for the second gene. Thus the substitution of a 'test' gene for the lacZ can allow experiments to be performed in these cell types with a uniformly transduced population which could not reliably be achieved by other means. For example, in the case of dendritic cells, cancer immunotherapy by loading with tumor antigens followed by return to the patient has often been considered, 10 and in the case of hematopoietic progenitor cells we are using the system to study the control of the cell cycle in these quiescent cells by a herpes vector-mediated gene delivery approach. This kind of approach might also be applicable to other cell types for which efficient gene transfer is as yet of low efficiency.
Thus, we have shown that GFP can be effectively expressed from a herpes vector both in vitro and in the mouse brain in vivo, and that 100% transduced populations of dendritic and quiescent CD34
+ hematopoietic progenitor cells can be produced when combined with subsequent flow cytometric sorting. Expression of a second gene together with GFP (in this case lacZ) allows the second gene to be delivered at an effective efficiency of 100%, and experimental protocols requiring gene delivery and which would not otherwise be possible in these cell types could thus be performed. The use of GFP reported here combines two advantages of a herpes vector system: first, that HSV can infect these cell types at a useful level of efficiency; and second, that multiple genes can easily be expressed without exceeding the packaging capabilities of the virus. While adenovirus vectors are able to transduce dendritic cells and hematopoietic progenitor cells, multiple gene expression is hard to achieve due to the limited packaging capabilities of the virus. GFP can thus be used as an aid to increase the effective transduction efficiency of a particular cell type, as a marker for in vivo gene delivery, for example, where it is required to carry out electrophysiological recordings from the successfully transduced cells, or as an aid for optimisation experiments in vitro or in vivo when gene delivery to a new cellular target is to be attempted using an HSV vector.
